NCT06163040Completed
A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan
Empliciti® (Elotuzumab) Post-Marketing Surveillance Study for Patients With Multiple Myeloma in Taiwan
Source: ClinicalTrials.gov · Last updated 31 Jul 2025
Brief summary (registry, in English)
This observational study aimed to assess the safety of elotuzumab when used in combination with pomalidomide and dexamethasone for the treatment of relapsed and refractory multiple myeloma (RRMM) in participants who had received at least two prior therapies, including lenalidomide and a proteasome inhibitor. The study will also assess the safety of elotuzumab when used in combination with lenalidomide and dexamethasone in RRMM participants who had received one to three prior therapies.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 7 (actual)
- First submitted
- 30 Nov 2023
- Start date
- 22 Dec 2023
- Primary completion date
- 17 Mar 2025
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Multiple myeloma
- NCT number
- NCT06163040
What you commit to
- Study type: Observational
- Participants enrolled: 7
- From 22 Dec 2023 to the primary completion date, 17 Mar 2025
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants with therapeutic indications for which elotuzumab in combination with pomalidomide/lenalidomide and dexamethasone has not been approved in Taiwan
- Participants who are contraindicated for treated with elotuzumab in combination with pomalidomide/lenalidomide and dexamethasone (as described in the Taiwan label)
Other
- Participants who participate in other interventional clinical trials
Who the study is looking for
- Age ≥ 18 years
- Confirmed diagnosis of RRMM
- Received ≥ 2 prior therapies including lenalidomide and a proteasome inhibitor
- Planning to receive elotuzumab in combination with pomalidomide and dexamethasone at physician's medical judgement OR
- Age ≥ 18 years
- Confirmed diagnosis of RRMM
- Received one to three prior therapies
- Planning to receive elotuzumab in combination with lenalidomide and dexamethasone at physician's medical judgement
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chang-Gung Memorial Hospital - Chiayi Coordinator of this site? Confirm its status | Chiayi City | Taiwan | Unknown status |
| Kaohsiung Medical University Chung-Ho Memorial Hospital Coordinator of this site? Confirm its status | Kaohsiung City | Taiwan | Unknown status |
| National Taiwan University Hospital Coordinator of this site? Confirm its status | Taipei | Taiwan | Unknown status |
| China Medical University Hospital Coordinator of this site? Confirm its status | Taoyuan City | Taiwan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.